Personalized Melanoma Vaccine Shows Strong, Lasting Benefit with Immunotherapy
TL;DR Summary
Moderna and Merck report promising results for a patient-tailored mRNA cancer vaccine paired with Keytruda in high-risk melanoma. The vaccine, designed from a patient’s tumor mutations (neoantigens), reduced recurrence or death by 49% versus immunotherapy alone and demonstrated durable immune memory over five years, signaling a potential breakthrough for personalized cancer vaccines and future skin-cancer prevention.
- Moderna’s Skin Cancer Vaccine Is Looking Seriously Promising ZME Science
- Moderna Stock Soars. Why a Cancer Vaccine Study Has Sparked a Rally. Barron's
- This innovation saved lives in the pandemic. Now it’s showing strength against cancer. The Washington Post
- Moderna, Merck Report Positive Results From Cancer-Vaccine Study The Wall Street Journal
- Benefit from Moderna’s skin cancer immunotherapy endures statnews.com
Reading Insights
Total Reads
1
Unique Readers
5
Time Saved
8 min
vs 9 min read
Condensed
97%
1,733 → 56 words
Want the full story? Read the original article
Read on ZME Science